The global, randomized, phase III ALTA-1L trial met its primary endpoint at the first pre-specified interim analysis, with Alunbrig (brigatinib) demonstrating a statistically significant improvement in progression-free survival compared to crizotinib in adults with anaplastic lymphoma kinase-positive locally advanced or metastatic non-small cell lung cancer who had not received a prior ALK inhibitor.
FDA approved Tibsovo (ivosidenib) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia who have a specific genetic mutation. This first drug in its class (IDH1 inhibitors) is approved for use with an FDA-approved companion diagnostic used to detect specific mutations in the IDH1 gene in patients with AML.
Genentech said the phase III IMpower132 study met its co-primary endpoint of progression-free survival and demonstrated that the combination of Tecentriq (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death compared to chemotherapy alone in the initial treatment of advanced non-squamous non-small cell lung cancer.
Analysis of cancer death data from 2008-2014 in New York state revealed high cancer mortality rates among U.S.-born blacks and Puerto Ricans and relatively low cancer mortality rates among Hispanic South Americans and Asians.
A signaling pathway that helps promote normal cell growth worsens a form of leukemia by taking control of another pathway better known for protecting cells from biological stress, a new study shows.
A study, published July 12 in JCI Insight, suggests that PD-1 inhibitors could be successfully incorporated into early-stage non-small cell lung cancer treatment, according to new research by Weill Cornell Medicine and NewYork-Presbyterian investigators.
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine. The findings were reported today online in JAMA Oncology.
Two new studies examining the use of aspirin and non-aspirin nonsteroidal anti-inflammatory drugs in connection to ovarian cancer found that women could benefit from daily aspirin consumption to reduce cancer risk and improve survival after diagnosis.
The gains in insurance coverage with the Patient Protection and Affordable Care Act have translated into improved health for young women with gynecologic cancers, who are getting diagnosed at earlier stages of their disease because of ACA benefits, a study by Johns Hopkins Medicine found.
Takeda Pharmaceutical Co. Ltd. announced the randomized, phase III TOURMALINE-MM3 study met its primary endpoint, demonstrating single-agent oral Ninlaro (ixazomib) as a maintenance therapy resulted in a statistically significant improvement in progression-free survival versus placebo.
